"Red Morphine Drops" for Symptomatic Treatment of Dyspnoea in Lung Cancer
This study is currently recruiting participants.
Verified by Sankt Lukas Hospice June 2006
Sponsored by: |
Sankt Lukas Hospice |
Information provided by: |
Sankt Lukas Hospice |
ClinicalTrials.gov Identifier: |
NCT00338481 |
|
Purpose
The purpose of this study is to test whether "red morphine drops" applied in the mouth are superior to an equivalent amount of morphine applied as subcutaneous injection for the relief of breathlessness in terminal patients suffering from primary lung cancer or lung metastases.
Condition |
Intervention |
Phase |
Dyspnea
Lung Neoplasms |
Drug: morphine |
Phase IV |
MedlinePlus related topics: Breathing Problems; Lung Cancer
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Active Control, Factorial Assignment, Efficacy Study
Primary Outcome Measures:
- Dyspnea on a VAS-scale 0-5-10-15-20-30-60 min after morphine administration.
Secondary Outcome Measures:
- Oxygen saturation and respiratory frequency 0-5-10-15-20-30-60 min after morphine administration.
Further study details as provided by Sankt Lukas Hospice:
Total Enrollment: 20
Study start: April 2006; Expected completion: January 2007
Breathlessness or dyspnea in terminal cancer patients with lung cancer is common and opioids such as morphine is the mainstay of symptomatic treatment. Subcutaneous administration of morphine provides fast symptomatic relief, but it has been the impression in our institution that "red morphine drops" applied orally may have equal or better efficacy and faster onset time.
Comparison: Patients with lung cancer or lung metastases with moderate to severe dyspnea at rest are treated with either orally applied "red morphine drops" or an equivalent amount of morphine applied subcutaneously.